Aurobindo Pharma receives USFDA Approval for Ibandronate Sodium Injection

Published On 2015-08-22 17:05 GMT   |   Update On 2015-08-22 17:05 GMT
At the estimate market size of $422 million for 12 months, the generic version of Prilosec delayed-release capsules by Aurobindo Pharma will be launched in the US

Aurobindo Pharma has received the green signal from the USFDA to market the generic version of Prilosec delayed-release capsule in the strengths of 10mg, 20mg, and 40 mg in the American market. The company has got the permission to manufacture and market Omeprazole delayed-release, used for short-term treatment of active duodenal ulcer in adults.

As confirmed by PTI,

The company's approved abbreviated new drug application (ANDA) is a generic version of AstraZeneca Pharmaceuticals' Prilosec capsules, confirmed the company in a media statement,
According to IMS, the product had an estimated market size of USD 422 million for the twelve months ended June 30.

In a separate statement, the company said it has received approval from the USFDA to market generic version of Hoffmann-La Roche's Boniva injection in the American market.

The company's Ibandronate Sodium injection is indicated for the treatment of osteoporosis in postmenopausal women.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News